Safety of Venetoclax and Ibrutinib in CLL
Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, discusses the safety profile of ibrutinib plus venetoclax in patients with chronic lymphocytic leukemia.
Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, discusses the safety profile of ibrutinib (Imbruvica) plus venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL).
According to Ghia, no out of the ordinary safety signals were reported. Neutropenia was the most common adverse event (AE), occurring in 33% of patients.
Additionally, there was also some mild grade diarrhea, according to Ghia. Most AEs observed were grade 1 and 2. Of the 156 patients, only 3 had to discontinue treatment due to toxicity.
One Arm of SEQUOIA Trial Shows 100% Response in High-Risk CLL/SLL
August 15th 2024Zanubrutinib with venetoclax led to an overall response rate of 100% when used for treating patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma with 17p deletions and/or TP53 mutations.
Read More
